| 3N2N | F:44-215; F:44-215; F:44-215; F:44-215; F:44-215; F:44-215 | THE CRYSTAL STRUCTURE OF TUMOR ENDOTHELIAL MARKER 8 (TEM8) EXTRACELLULAR DOMAIN |
| 1SHT | X:44-213 | CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR A DOMAIN OF HUMAN CAPILLARY MORPHOGENESIS PROTEIN 2: AN ANTHRAX TOXIN RECEPTOR |
| 1SHU | X:44-213 | CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR A DOMAIN OF HUMAN CAPILLARY MORPHOGENESIS PROTEIN 2: AN ANTHRAX TOXIN RECEPTOR |
| 1T6B | Y:44-210 | CRYSTAL STRUCTURE OF B. ANTHRACIS PROTECTIVE ANTIGEN COMPLEXED WITH HUMAN ANTHRAX TOXIN RECEPTOR |
| 1TZN | o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213; o:1044-1213 | CRYSTAL STRUCTURE OF THE ANTHRAX TOXIN PROTECTIVE ANTIGEN HEPTAMERIC PREPORE BOUND TO THE VWA DOMAIN OF CMG2, AN ANTHRAX TOXIN RECEPTOR |
| 1Q0P | A:245-432 | A DOMAIN OF FACTOR B |
| 1RRK | A:245-443 | CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B |
| 1RS0 | A:245-443 | CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH DI-ISOPROPYL-PHOSPHATE (DIP) |
| 1RTK | A:245-443 | CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH 4-GUANIDINOBENZOIC ACID |
| 2OK5 | A:245-443 | HUMAN COMPLEMENT FACTOR B |
| 2WIN | L:245-443; L:245-443; L:245-443; L:245-443 | C3 CONVERTASE (C3BBB) STABILIZED BY SCIN |
| 2XWB | H:245-443; H:245-443 | CRYSTAL STRUCTURE OF COMPLEMENT C3B IN COMPLEX WITH FACTORS B AND D |
| 2XWJ | L:245-443; L:245-443; L:245-443; L:245-443 | CRYSTAL STRUCTURE OF COMPLEMENT C3B IN COMPLEX WITH FACTOR B |
| 2ODP | A:234-432 | COMPLEMENT COMPONENT C2A, THE CATALYTIC FRAGMENT OF C3- AND C5-CONVERTASE OF HUMAN COMPLEMENT |
| 2ODQ | A:234-432 | COMPLEMENT COMPONENT C2A, THE CATALYTIC FRAGMENT OF C3- AND C5-CONVERTASE OF HUMAN COMPLEMENT |
| 1PT6 | B:144-327; B:144-327 | I DOMAIN FROM HUMAN INTEGRIN ALPHA1-BETA1 |
| 1QC5 | B:334-517; B:334-517 | I DOMAIN FROM INTEGRIN ALPHA1-BETA1 |
| 1V7P | C:145-334 | STRUCTURE OF EMS16-ALPHA2-I DOMAIN COMPLEX |
| 1LFA | B:131-306; B:131-306 | CD11A I-DOMAIN WITH BOUND MN++ |
| 1MJN | A:131-306 | CRYSTAL STRUCTURE OF THE INTERMEDIATE AFFINITY AL I DOMAIN MUTANT |
| 1MQ8 | D:131-306; D:131-306 | CRYSTAL STRUCTURE OF ALPHAL I DOMAIN IN COMPLEX WITH ICAM-1 |
| 1MQ9 | A:131-300 | CRYSTAL STRUCTURE OF HIGH AFFINITY ALPHAL I DOMAIN WITH LIGAND MIMETIC CRYSTAL CONTACT |
| 1MQA | A:131-300 | CRYSTAL STRUCTURE OF HIGH AFFINITY ALPHAL I DOMAIN IN THE ABSENCE OF LIGAND OR METAL |
| 1RD4 | D:131-306; D:131-306; D:131-306; D:131-306 | AN ALLOSTERIC INHIBITOR OF LFA-1 BOUND TO ITS I-DOMAIN |
| 1XDD | B:131-306; B:131-306 | X-RAY STRUCTURE OF LFA-1 I-DOMAIN IN COMPLEX WITH LFA703 AT 2.2A RESOLUTION |
| 1XDG | B:131-306; B:131-306 | X-RAY STRUCTURE OF LFA-1 I-DOMAIN IN COMPLEX WITH LFA878 AT 2.1A RESOLUTION |
| 1XUO | B:131-302; B:131-302 | X-RAY STRUCTURE OF LFA-1 I-DOMAIN BOUND TO A 1,4-DIAZEPANE-2,5-DIONE INHIBITOR AT 1.8A RESOLUTION |
| 1ZON | A:131-306 | CD11A I-DOMAIN WITHOUT BOUND CATION |
| 1ZOO | B:131-306; B:131-306 | CD11A I-DOMAIN WITH BOUND MAGNESIUM ION |
| 1ZOP | B:131-306; B:131-306 | CD11A I-DOMAIN WITH BOUND MAGNESIUM ION |
| 2O7N | A:131-306 | CD11A (LFA1) I-DOMAIN COMPLEXED WITH 7A-[(4-CYANOPHENYL) METHYL]-6-(3,5-DICHLOROPHENYL)-5-OXO-2,3,5,7A-TETRAHYDRO-1H-PYRROLO[1,2-A]PYRROLE-7-CARBONITRILE |
| 3M6F | A:131-306 | CD11A I-DOMAIN COMPLEXED WITH 6-((5S,9R)-9-(4-CYANOPHENYL)-3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-DIOXO-1,3,7- TRIAZASPIRO[4.4]NON-7-YL) NICOTINIC ACID |
| 1JLM | A:134-312 | I-DOMAIN FROM INTEGRIN CR3, MN2+ BOUND |
| 1M1U | A:134-312 | AN ISOLEUCINE-BASED ALLOSTERIC SWITCH CONTROLS AFFINITY AND SHAPE SHIFTING IN INTEGRIN CD11B A-DOMAIN |
| 1MF7 | A:134-312 | INTEGRIN ALPHA M I DOMAIN |
| 1NA5 | A:134-312 | INTEGRIN ALPHA M I DOMAIN |
| 1N3Y | A:132-310 | CRYSTAL STRUCTURE OF THE ALPHA-X BETA2 INTEGRIN I DOMAIN |
| 3K71 | G:132-310 | STRUCTURE OF INTEGRIN ALPHAX BETA2 ECTODOMAIN |
| 1M10 | A:514-691 | CRYSTAL STRUCTURE OF THE COMPLEX OF GLYCOPROTEIN IB ALPHA AND THE VON WILLEBRAND FACTOR A1 DOMAIN |
| 1OAK | A:514-691 | CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR (VWF) A1 DOMAIN IN COMPLEX WITH THE FUNCTION BLOCKING NMC-4 FAB |
| 1SQ0 | A:514-691 | CRYSTAL STRUCTURE OF THE COMPLEX OF THE WILD-TYPE VON WILLEBRAND FACTOR A1 DOMAIN AND GLYCOPROTEIN IB ALPHA AT 2.6 ANGSTROM RESOLUTION |
| 1U0N | A:514-691 | THE TERNARY VON WILLEBRAND FACTOR A1-GLYCOPROTEIN IBALPHA-BOTROCETIN COMPLEX |
| 1UEX | C:514-691 | CRYSTAL STRUCTURE OF VON WILLEBRAND FACTOR A1 DOMAIN COMPLEXED WITH SNAKE VENOM BITISCETIN |
| 3PPV | A:1498-1659 | CRYSTAL STRUCTURE OF AN ENGINEERED VWF A2 DOMAIN (N1493C AND C1670S) |
| 3PPW | A:1498-1659 | CRYSTAL STRUCTURE OF THE D1596A MUTANT OF AN ENGINEERED VWF A2 DOMAIN (N1493C AND C1670S) |
| 3PPX | A:1498-1659 | CRYSTAL STRUCTURE OF THE N1602A MUTANT OF AN ENGINEERED VWF A2 DOMAIN (N1493C AND C1670S) |
| 3PPY | A:1498-1659 | CRYSTAL STRUCTURE OF THE D1596A/N1602A DOUBLE MUTANT OF AN ENGINEERED VWF A2 DOMAIN (N1493C AND C1670S) |
)
)